A Scottish research company is designing a new generation of antibiotics using academic expertise to combat drug-resistant bacteria such as the hospital "superbug" methicillin-resistant Staphylococcus aureus (MRSA). MGB Biopharma is to commercialise a new class of antibacterial product based on University of Strathclyde research. About £2 million in funding has been secured for the project, which uses technology licensed from Strathclyde. So far it has shown positive results in combating gram-negative and gram-positive bacteria, including MRSA.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login